Retatrutide: A Triple Agonist Still in Trials, Already Everywhere on the Grey Market
Retatrutide draws 450,000 searches a month for a compound that has not completed phase 3. That gap between public interest and completed evidence is the most important thing to understand about it.
10mg
Typical vial
$98
Lowest tracked
$152
Median price
94
Vendors listing
Where the trials stand
Retatrutide targets three receptors — GIP, GLP-1, and glucagon. Published phase 2 results reported substantial effects on metabolic endpoints, and phase 3 programmes are ongoing.
Our index references around 46 studies. Evidence grade: Emerging. Promising phase 2 data is not the same as a completed evidence base, and attrition between phase 2 and phase 3 is common.
Why pre-approval supply is riskier
There is no licensed reference product to compare against, no established impurity profile in the public domain, and no regulatory oversight of anything sold. Analytical verification carries more weight here than in any other category.
Pricing
10mg vials run roughly £77 to £120, the highest band in our index. Fewer vendors list it — around 94 in our tracking — so price competition is limited.
Supplier scoring
We look for full-catalogue certificate coverage, independent lab links, and honest labelling of investigational status. Vendors implying approval or clinical availability are downgraded regardless of test quality.
Frequently asked
Is retatrutide approved anywhere?
Not at the time of writing. It remains an investigational compound in ongoing trials.
Why is it the most expensive peptide tracked?
Complex synthesis, no licensed supply, and demand well ahead of availability.
Search focus for this profile
retatrutide — 450,000/mo searches, difficulty 66/100 — difficult. Source: Semrush (UK database).
Supporting terms covered: retatrutide review, triple agonist peptide, retatrutide phase 3.
Everything below describes published research and market data. Nothing here is medical advice, and none of these compounds are sold or supplied by CheckALab.
More in Metabolic
Semaglutide
GLP-1 receptor agonist with a large human clinical trial record in metabolic research.
Tirzepatide
Dual GIP/GLP-1 agonist studied in large randomized metabolic endpoints.
Survodutide
GLP-1 and glucagon dual agonist with published phase 2 metabolic and liver outcomes.
5-Amino-1MQ
Small-molecule NNMT inhibitor studied in adipocyte and metabolic models.
Liraglutide
First-generation GLP-1 agonist with a large clinical trial literature behind it.
Lipo-C
Lipotropic compounded solution of methionine, inositol, choline and B vitamins.
AOD9604
Growth hormone fragment 176-191 studied for lipolytic activity, with human trial data.
Mazdutide
GLP-1 and glucagon dual agonist based on oxyntomodulin, with phase 3 data in China.
MOTS-c
Mitochondrial-derived peptide studied in exercise metabolism and insulin sensitivity models.